What We Do
Radiopharmaceutical therapy (RPT) is an attractive alternative to chemotherapy for many cancer patients. RPT works by tagging a radionuclide to a drug-carrier that specifically targets tumor cells. Once the drug locks onto a tumor cell, the radionuclide delivers a toxic dose of radiation. As a much more targeted radionuclide therapy, it spares healthy tissue and can provide better outcomes.
Today’s RPT standard of care doesn’t address interpatient variability. Standardized dosing can fail to achieve a cure due to underdosing, or present a risk of induced side effects due to overdosing.
Studies have shown the uptake of the drug in tumors or critical organs can vary as much as five-fold between patients. Dosimetry-guided RPT (DG-RPT) helps tailor treatment plans to fit a patient’s individual drug-interaction (pharmacokinetics). A personalized treatment can potentially lead to longer overall survival, increased tumor response, and higher quality of life.
The ability to measure the absorbed dose (AD) delivered to each tumor or critical structure following administration of therapeutic activity.*
The ability to define an optimum treatment course for a patient based on individual PK information, including the number of therapy cycles and size of administered activity per cycle.*
Because a patient's drug interaction may change over the course of therapy, it is important to have the ability to adapt the treatment plan in response.*
GPU-Accelerated RPT Dose Assessment
Torch™ simplifies the otherwise complex task of analyzing a patient’s nuclear medicine scans to develop a personalized assessment, including estimates of patient-specific pharmacokinetics and calculation of dose to the patient’s tumors and critical structures. *
*510(k) pending. Torch™ is under FDA review and is NOT available for sale or clinical use.